Retrospective Analysis of Clinical Features and Treatment Response of Feline Pruritic Skin Diseases
YAN Lang,LI Xinqiu,GAO Pingping,JIANG Wanlu,ZHANG Di
DOI: https://doi.org/10.11843/j.issn.0366-6964.2023.03.042
2023-01-01
Abstract:The study mainly focuses on the feline pruritic skin diseases, the aim was to investigate and summarize the clinical features, analyzed the clinical efficacy of common treatment options, and focused on the application of oclacitinib in feline hypersensitivity associated dermatoses, and compared the efficacy with prednisolone. We collected 138 cases who visited China Agricultural University Veterinary Teaching Hospital between January 2021 and March 2022, the basic information, clinical features, treatment options, clinical efficacy, and other information were recorded and analyzed. Among the 138 cases, the breed with the highest proportion was British short hair（27.54%）, the male-to-female ratio was 1.42∶1, and the average age at consultation was 2.84 years old. Although the efficacy rate of off-label use of oclacitinib in the treatment of feline hypersensitivity associated dermatoses is slightly lower than that of prednisolone, but for effective cases, the efficacy is significant（P＜0.05）, and there is no significant difference in the improvement of symptoms（P＞0.05）. This study showed that feline pruritic skin disease has no obvious breed and gender orientation, and the onset is mostly in young age. The most common type of lesions is scratches, and the most common lesions are on the head and neck. In the etiological diagnosis of pruritic skin disease in cats, hypersensitivity associated dermatoses in cats dominates, more attention should be paid to it. In terms of treatment, the combination of drugs according to the situation is better. Based on the mechanism of oclacitinib and prednisolone, the safety of the former is higher than that of the latter, so oclacitinib can be used instead of prednisolone for pruritus control of feline hypersensitivity associated dermatoses, but the oclacitinib in cats is off-label used, so further research is needed for the safety and dosage of oclacitinib in cats.